Year 2024 / Volume 116 / Number 5
Letter
Mesalazine-induced esophageal ulcers. A rare adverse effect

294-295

DOI: 10.17235/reed.2023.9723/2023

Raúl José Díaz Molina, Carlos Comesaña Castellar, Marcelo García Hernández, Carmen Garrido Durán, Marco Antonio Martínez Ortega, Daniel Ginard Vicens,

Abstract
31-year-old woman. Diagnosis of ulcerative proctitis in February/2022. Calprotectin 1832 μg/g. Colonoscopy: erythematous, friable and erosive mucosa up to 10 cm from the anal margin. Pathology: compatible with ulcerative colitis with moderate activity. Start of oral mesalazine (3 gr/24 h granules) and topical (1 gr/24 h suppository). After three months, she achieved clinical remission. Calprotectin 57 μg/g. Two months later, she consulted for solid dysphagia, loss of 10 kg, and low-grade fever for a month. Fifteen days before, she went to an emergency room where Prednisone 50 mg/24 h was started. On the day of the assessment, she was receiving 30 mg with no improvement. The next day, gastroscopy showed 6-12 mm esophageal ulcers with non-confluent shallow geographic borders, biopsies were taken. Viral serologies and HLA B51 were requested. Given the severity of the symptoms, empirical treatment was started with Valaciclovir 1 g/12 h. Serologies: IgG for Ebstein Barr virus, cytomegalovirus and herpes virus with negative IgM. Cytomegalovirus viral load: <30 IU/ml. Pathology: acute extensively ulcerated esophagitis, inflammatory infiltrate and some eosinophils with negative histochemical staining for fungi, cytomegalovirus and herpes virus I and II. HLA B51 was negative. Valaciclovir and mesalazine are discontinued after seven days given the known relationship of the latter with low-grade fever and, exceptionally, with esophageal pathology. Three days later, the patient reported clear improvement in dysphagia from the day the mesalazine was discontinued. After eight months, she was still asymptomatic. Upon resolution of the symptoms, control gastroscopy was not performed, and mesalazine has not been reintroduced due to its probable causal association. Mesalazine has an excellent safety profile. Adverse effects include fever, headache, diarrhea and
Share Button
New comment
Comments
No comments for this article
References
1- López-Cepero Andrada JM, López Silva M, Salado Fuentes M, et al. Ulcera esofágica por mesalazina [Esophageal ulcer due to mesalazine]. Gastroenterol Hepatol. 2000 Aug-Sep;23(7):362.
2- Park J, Cheon JH. Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α. Korean J Intern Med. 2022 Sep;37(5):895-905.
3- Tsujii Y, Nishida T, Osugi N, et al. Classification and clinical features of adverse drug reactions in patients with ulcerative colitis treated with 5-aminosalicylate acid: a single-center, observational study. Scand J Gastroenterol. 2022 Feb;57(2):190-196
Related articles

Letter

Mesalazine induced interstitial pneumonitis in the COVID era

DOI: 10.17235/reed.2022.8635/2021

Case Report

Effects of mesalazine enemas on lymphoid follicular proctitis

DOI: 10.17235/reed.2018.5481/2018

Case Report

Topical mesalazine as a cause of Stevens-Johnson syndrome

DOI: 10.17235/reed.2018.5429/2017

Letter to the Editor

Idiopathic esophageal ulcer as an initial manifestation of HIV infection

DOI: 10.17235/reed.2017.5135/2017

Citation tools
Díaz Molina R, Comesaña Castellar C, García Hernández M, Garrido Durán C, Martínez Ortega M, Ginard Vicens D, et all. Mesalazine-induced esophageal ulcers. A rare adverse effect. 9723/2023


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 1073 visits.
This article has been downloaded 90 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 15/05/2023

Accepted: 03/06/2023

Online First: 22/06/2023

Published: 09/05/2024

Article Online First time: 38 days

Article editing time: 360 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology